Edition:
United Kingdom

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

1.89USD
23 Apr 2019
Change (% chg)

-- (--)
Prev Close
$1.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
72,259
52-wk High
$5.10
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Adamis Pharmaceuticals Submits New Drug Application To FDA For Its Naloxone Pre-Filled Syringe
Monday, 31 Dec 2018 

Dec 31 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO FDA FOR ITS NALOXONE PRE-FILLED SYRINGE.  Full Article

Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA INDICATED IF NO MAJOR DEFICIENCIES IDENTIFIED, THEY ARE TARGETING SEPTEMBER 3, 2018 TO COMMUNICATE PROPOSED LABELING.  Full Article

Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE.  Full Article

Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI.ADAMIS PHARMACEUTICALS CORP - SUBMISSION OF A PRIOR APPROVAL SUPPLEMENT TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDIATRIC VERSION (0.15MG) OF SYMJEPI.  Full Article

Adamis Pharmaceuticals gets FDA approval for co's epinephrine pre-filled syringe
Thursday, 15 Jun 2017 

June 15 (Reuters) - Adamis Pharmaceuticals Corp ::Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe.Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe.FDA has also approved PFS trade name of Symjepi.‍FDA approved Adamis' epinephrine injection, USP, 1:1000 for emergency treatment of allergic reactions including anaphylaxis​.Are preparing to submit second NDA for junior version of Symjepi to FDA.Expect to build inventory levels in preparation for anticipated launch in H2 of year for co's epinephrine pre-filled syringe.  Full Article